CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Omnimmune Holdings Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Omnimmune Holdings Inc
4600 Post Oak Place Dr Ste 352
Phone: (713) 622-8400p:713 622-8400 HOUSTON, TX  77027-9608  United States Ticker: OMMHOMMH

This company ceased filing statements with the SEC on 4/15/2011.

Business Summary
Omnimmune Holdings, Inc. (Omnimmune) is a development-stage biotechnology company integrating complementary cancer therapeutic, diagnostic and prognostic technologies. The Company is the holding company of Omnimmune Corp. Omnimmune has acquired licensed rights to diagnostic and platform monoclonal antibody technologies. Omnimmune’s hCGß and related technologies, which are protected through an expanding intellectual property portfolio, have been developed at institutions including Columbia University of New York, New York (Columbia), The Allegheny-Singer Research Institute of the West Penn Allegheny Health System, Pittsburgh, Pennsylvania (Allegheny) and The Institute Gustave Roussy, Paris, France (IGR).
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/201012/31/2009YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chief Executive Officer, Director TravisMcPhee 27 2/22/2007 2/22/2007

Business Names
Business Name
InVitro Technologies, Inc.
OMMH
Omnimmune Corporation

General Information
Number of Employees: 2 (As of 12/31/2009)
Outstanding Shares: 9,355,921 (As of 11/19/2010)
Shareholders: 173
Stock Exchange: OTC
Federal Tax Id: 263128407
Fax Number: (302) 655-5049


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, August 29, 2023